Do a search on Youtube for “vitamin c IV cancer cure” and you will get a surprising quantity and variety of news reports, interviews and testimonials about the effectiveness of Vitamin C in the fight against cancer. Here is a screenshot:
Never let anyone tell you it’s too late to start working on your body. Case in point:
Merrill Matzinger – age 95 – does cardio, lifts weights and starts his daily workouts with 1,500 crunches.
“All the doctors that have treated me can’t believe what they’re seeing,” Matzinger said. “That’s encouraging, to go to the doctor and have compliments rather than prescriptions.”
He is also legally blind — but he hasn’t let that slow him down. Matzinger says he only remembers missing one workout in the last 20 years. He’s approaching the centenarian mark and his workout puts youngsters to shame!
This is information that needs to be disseminated:
Intravenous Ascorbate as a Chemotherapeutic and Biologic Response Modifying Agent
by The Center for the Improvement of Human Functioning, International, Inc., Bio-Communications Research Institute.Reprinted with permission.
(Emphasis added by DoctorYourself.com editor Andrew Saul)
Additional research papers may be read athttp://brightspot.org/cresearch/index.shtml
For over 15 years we have studied high dose intravenous ascorbic acid (IAA) as an adjunctive therapy for cancer patients. Initially, doses of 15 g per infusion were used, once or twice per week. These doses improved patient’s sense of well being, reduced pain, and in many cases prolonged life beyond prognostications of oncologists.
Twelve years ago, we used infusions of 30 grams of intravenous ascorbic acid, twice per week, and found that metastatic lesions in the lung and liver of a man with a primary renal cell carcinoma disappeared in a matter of weeks (1). At that time we believed IAA was useful for patients with cancer solely through two biological response modifier mechanisms: increased production of extracellular collagen (“walling off’ the tumor as proposed by Cameron and Pauling) and enhancement of immune function. We subsequently reported a case of resolution of bone metastases in a patient with primary breast cancer (1A) using infusions of 100 grams, once or twice per week (2).
In a recent publication (3) we presented evidence that ascorbic acid and its salts (AA) could be more than biological response modifiers. We found that ascorbic acid is preferentially toxic to tumor cells suggesting that it could be useful as a chemotherapeutic agent. Preferential toxicity occurred in vitro in multiple tumor cell types. We also presented data suggesting that plasma concentrations of ascorbate required for killing tumor cells were achievable in humans. Others have described in vivo toxicity in multiple tumor types and animal models (4-8).
Here we wish to summarize our experience using IAA for approximately 50 patients with cancer. We include our protocol, precautions, and case studies of two patients treated for metastatic renal cell carcinoma.
From our studies (3) we concluded that:
Tumor cells are more susceptible to the effects of high-dose, ascorbate-induced peroxidation products because of a relative catalase deficiency; and,
Concentrations of ascorbate high enough to kill tumor cells likely can be achieved in humans.
This study was passed along by Dr. Mercola and is well worth reading:
by Vincent Racaniello, March 29/2010
Delwart laboratory obtained samples of eight infectious attenuated viral vaccines from the manufacturers: oral poliovirus vaccine (OPV, Bharat Biotech), rubella (Meruvax-II, Merck), measles (Attenuvax, Merck), yellow fever (YF-Vax, Sanofi Pasteur), human herpes 3 (Varivax, Merck), rotavirus (Rotarix, GlaxoSmithKline; and Rotateq, Merck) and multivalent measles-mumps-rubella (MMR-II, Merck). The vaccines were treated with DNAse and RNAse to remove nucleic acids that are not protected by viral capsids. Nucleic acid was then extracted from the vaccine, amplified by polymerase chain reaction, and subjected to DNA sequencing. A total of 501,753 sequence ‘reads’ were done.
The sequence analysis revealed the expected vaccine strains in each preparation, and in three cases, other unexpected viral sequences. The retrovirus avian leukosis virus was found in the measles vaccine, but at a very low level (700 nucleotides from 4 sequence reads). A virus similar to simian retrovirus was identified in Rotateq (276 nucleotides from 1 sequence read). Significant levels of porcine cirovirus 1 were found in Rotarix. The entire viral genome sequence was deduced from 6344 sequence reads, comprising over 40% of the reads done for that vaccine.
The avian leukosis virus sequences found in the measles vaccine are in intact virions, as DNA treatment of the vaccines did not prevent their detection by polymerase chain reaction (PCR). However simian retrovirus DNA was not detected by PCR after DNAse treatment of Rotateq. Therefore the viral DNA detected in Rotateq vaccine most likely originates from host DNA present in the vaccine preparation. The cells used to produce Rotateq are Vero cells – African green monkey kidney cells. A defective form of simian retrovirus DNA, called proviral DNA, is integrated into Vero cell DNA.
How did a porcine virus contaminate Rotarix, which is produced in Vero cells? The answer is not known, but the authors speculate that the culprit might be porcine trypsin, which is used during the propagation of Vero cells. Over 100,000 porcine circovirus 1 DNA molecules were detected in each vaccine dose, fully 10 times higher than the amount of rotavirus present. However, it’s not known if the porcine circovirus present is infectious.